IM19 CAR-T (Imunopharm) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This IM19 CAR-T (Imunopharm) Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 24 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether IM19 CAR-T (Imunopharm) can convert its Autologous CAR-T profile and CD19 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | IM19 CAR-T (Imunopharm) (query alias: IM19 CAR-T (Imunopharm)) |
|---|---|
| Modality / target | Autologous CAR-T; CD19; CD19 modulators, T lymphocyte replacements |
| Highest global status | NDA/BLA |
| Originator | Beijing Imunopharm Technology Co., Ltd. |
| Active developers | Beijing Imunopharm Technology Co., Ltd., Beijing Yimiao Medical Technology Co., Ltd., Shandong Jinsai Biotechnology Co., Ltd. |
The MCP disease footprint includes CD19 positive Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, B-Cell Leukemia. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT05309213 | Phase 1/2 | Unknown status | 58 | Incidence of Treatment Related adverse events (AEs) |
| NCT06690359 | Early Phase 1 | Not yet recruiting | 12 | IgA nephropathy-Main safety endpoint（Adverse event incidence rate） |
| NCT05480501 | Early Phase 1 | Unknown status | 9 | Incidence of adverse events (AEs) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Refractory Systemic Lupus Erythematosus: an open-label pilot study
Phase 1; n=6; evaluation: Positive. Reported fields: CRS = grade 1 CRS in 4 patients
Phase I Study of a CD19-Directed CAR-T Cell Therapy for Relapsed/Refractory Mantle Cell Lymphomas(MCL)
临床1期; n=11; evaluation: 积极. Reported fields: CR(28-day) = 91 %
4423 Phase I Study of a CD19-Directed CAR-T Cell Therapy for Relapsed/Refractory Mantle Cell Lymphomas(MCL)
Phase 1; n=5; evaluation: not stated. Reported fields: AUC = 860 day×CAR+ cells/L
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
IM19 CAR-T (Imunopharm) addresses CD19 positive Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, B-Cell Leukemia. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Autologous CAR-T—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2024-08-04 | 华东医药与艺妙神州宣布就CD19自体CAR-T产品IM19注射液达成商业化合作 | Phase 2 | US$17.3M upfront; US$131.7M milestones |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 24 July 2026. Counts and status fields may change as source records update.
